Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended for patients who have not responded to two other, conventional antidepressants which can ...

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...

for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate ...

6 The mechanism by which esketamine exerts its antidepressant effect is unknown. Backed by more than a decade of research and almost six years of real-world evidence, SPRAVATO® has proven to be a ...